Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses PSMA and its role in prostate cancer treatment.
- PSMA (Prostate Specific Membrane Antigen) is a protein distinct from PSA in that it is a folate transporter and is expressed in about 90% of prostate cancer specimens
- PSMA seems to be upregulated after hormone therapy and may be downregulated as patients progress in the pathway of castration resistance
- PSMA is a target of ProstaScint, an FDA approved agent for imaging prostate cancer
- PSMA is being used as an imaging agent and a therapeutic target
- Researchers have been looking into combining anti-PSMA antibody with an agent that targets tubulin, which may deliver chemotherapy more effectively
- The anti-PSMA antibody has demonstrated activity in patients who failed docetaxel and cabazitaxel